Arvinas, Inc. (ARVN)
NASDAQ • Healthcare
Last close at September 9, 2026 at 20:00 UTC
Metrics Over Time
Where the Money Goes
Q2 2026In plain terms: out of every $100 in revenue, Arvinas, Inc. keeps $68 as net profit.
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
Nov 4
in 55 daysQ4 2026% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
Arvinas’ second fiscal quarter of 2026 featured negative operating cash flow, with operating cash flow at -$48.3 million, as it continued to fund development of its targeted protein degradation programs; the company reported the results on August 4, 2026. Looking ahead, next-period consensus calls for EPS of -$0.87 on revenue of $16.8 million.
About Arvinas, Inc.
Arvinas, Inc. is a NASDAQ-listed biotechnology company that develops protein-degradation medicines aimed at eliminating disease-causing proteins. Its business centers on identifying, advancing, and marketing these therapies, and it generated $262.6 million of revenue in FY2025 through a model built around partnered drug development and clinical-stage candidates.
Today's Snapshot
The session opened with ARVN 1% lower at 8.67, in line with a flat sector.
Trading Volume
Below 10d avg (529.8K)
222.1K
vs S&P 500 Today
Moderate Outperformance
+0.31%
Updated: September 10, 2026 at 14:56 UTC
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$8.91 - $9.88Sell
- RSI (14)43.53Neutral
- Stochastic %K (14, 3, 3)11.37Buy
- MACD Level (12, 26)0.08Neutral
Peers & Related Assets
Get premium market insights delivered directly to your inbox.